The company issued such a statement following a statement from the US National Institute of Allergy and Infectious Diseases (NIAID) stating that outdated information may have been used in deciding that AstraZeneca The Covid-19 vaccine is very effective.
“We have reviewed the preliminary assessment of the initial analysis and the results were in line with the interim analysis,” AstraZeneca.
“We plan to release the results of the initial analysis within 48 hours,” the company said.
AstraZeneca“On Monday, it announced that Phase III trials in the United States show that AstraZeneca The efficacy of the developed Covid-19 vaccine is 79%.
Although AstraZeneca The vaccine has been approved in more than 50 countries and has not yet been given the green light in the United States.
In Europe AstraZeneca The use of the vaccine was delayed by concerns about blood clots, which led to a number of countries temporarily suspending the use of the vaccine.
France, Germany and several other countries announced last week that they would resume AstraZeneca Use of Covid-19 vaccine.
Global experts and AstraZeneca emphasizes that the vaccine is safe.
Criticism of European Union (EU) officials AstraZeneca has also earned delays in the delivery of vaccine doses.
German Chancellor Angela Merkel on Tuesday supported a proposal to potentially block EU production AstraZeneca export of vaccine doses outside the block
–
